China Revokes Licenses For Shanghai Hualian Leukemia Drugs Found Contaminated (China)
This article was originally published in PharmAsia News
Executive SummaryChina revoked the license of Shanghai Hualian Pharmaceutical in the wake of an investigation that found it was marketing contaminated leukemia drugs that harmed patients. The company's license was canceled and the employees responsible have been detained, according to the State FDA. The agency accused the employees of a "systematically organized" cover-up during the government investigation of a case of several children injected with methotrexate who developed leg pains and difficulty walking. Use of the drug and another based on cytarabin hydrochloride were ordered suspended in September. The parent company, Shanghai Pharmaceutical Group, was ordered to compensate the families of the patients. (Click here for more ) "Cancer Drug Company Slammed After Probe" Shanghai Daily (China) (12/13/07)
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.